Cytokine-mediated inflammation is increasingly recognized for playing a vital role in the pathophysiology of a wide range of brain disorders, including neurodegenerative, psychiatric, and neurodevelopmental problems. Pro-inflammatory cytokines such as interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) cause neuroinflammation, alter brain function, and accelerate disease development. Despite progress in understanding these pathways, effective medicines targeting brain inflammation are still limited. Traditional anti-inflammatory and immunomodulatory drugs are effective in peripheral inflammatory illnesses. Still, they face substantial hurdles when applied to the central nervous system (CNS), such as the blood–brain barrier (BBB) and unwanted systemic effects. This review highlights the developing treatment techniques for modifying cytokine-driven neuroinflammation, focusing on advances that selectively target critical cytokines involved in brain pathology. Novel approaches, including cytokine-specific inhibitors, antibody-based therapeutics, gene- and RNA-based interventions, and sophisticated drug delivery systems like nanoparticles, show promise with respect to lowering neuroinflammation with greater specificity and safety. Furthermore, developments in biomarker discoveries and neuroimaging techniques are improving our ability to monitor inflammatory responses, allowing for more accurate and personalized treatment regimens. Preclinical and clinical trial data demonstrate the therapeutic potential of these tailored techniques. However, significant challenges remain, such as improving delivery across the BBB and reducing off-target effects. As research advances, the creation of personalized, cytokine-centered therapeutics has the potential to alter the therapy landscape for brain illnesses, giving patients hope for better results and a higher quality of life.

Cytokine-mediated inflammation is becoming recognized as a vital role in the pathophysiology of a wide range of brain illnesses, including neurodegenerative, psychiatric, and neurodevelopmental problems. Pro-inflammatory cytokines such as interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) cause neuroinflammation, alter brain function, and accelerate disease development. Despite progress in understanding these pathways, effective medicines to target brain inflammation are still limited. Traditional anti-inflammatory and immunomodulatory drugs are effective in peripheral inflammatory illnesses. Still, they confront substantial hurdles when used on the central nervous system, such as the blood-brain barrier and unwanted systemic effects. The review highlighted the developing treatment techniques for modifying cytokine-driven neuroinflammation, focusing on advances that selectively target critical cytokines involved in brain pathology. Novel approaches, including cytokine-specific inhibitors, antibody-based therapeutics, gene and RNA-based interventions, and sophisticated drug delivery systems like nanoparticles, promise to lower neuroinflammation with greater specificity and safety. Furthermore, developments in biomarker discoveries and neuroimaging techniques improve our ability to monitor inflammatory responses, allowing for more accurate and personalized treatment regimens. Preclinical and clinical trial data demonstrate the therapeutic potential of these tailored techniques. However, significant challenges remain, such as improving delivery across the blood-brain barrier and reducing off-target effects. As research advances, the creation of personalized, cytokine-centered therapeutics has the potential to alter the therapy landscape for brain illnesses, giving patients hope for better results and a higher quality of life.

The pharmacological potential of marine alkaloids is enormous due to their diverse bioactivities. In this work, we performed a comprehensive computational analysis of marine alkaloids, including Calcardine C, Ernstine A, Naamine H, Naamine I, Naamidine J, Naamidine K, Phorbatopsin D, and Phorbatopsin E, in connection with Mycothiol S-conjugate amidase (MycoSCoA), an essential enzyme for Mycobacterium tuberculosis metabolism. Frontier molecular orbital (FMO) analysis and geometry optimization show that Naamidine J is the most stable compound; its low HOMO–LUMO gaps suggest high reactivity. According to electrostatic potential mapping, naamidine K has the highest charge distribution, which is in line with a higher binding potential. The strong intramolecular charge transfer of the lead compounds was further confirmed by Natural Bond Orbital (NBO) analysis. Molecular docking studies show that Naamidine K and Naamidine J have the highest binding affinities with MycoSCoA (-10.6 and -9.3 kcal/mol, respectively). These substances use a range of hydrophobic and hydrogen bonding interactions to create stable complexes. It is noteworthy that Naamidine J exhibited superior binding to 4EWL (-9.3 kcal/mol), which was sustained by a network of hydrogen bonds and π-interactions. The selectivity of the marine alkaloids was highlighted by the weakest interactions, which were shown by BOG and GOL. This in silico study highlights Naamidine K and J as promising candidates for further anti-tuberculosis drug development in general.